Compositions and methods for determining anti-viral drug...

Details Compositions and methods for determining anti-viral drug... Compositions and methods for determining anti-viral drug...

2005-09-13

2005-09-13

Ketter, James (Department: 1636)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving nucleic acid

C435S320100, C435S369000, C435S370000

Reexamination Certificate

active

06942969

ABSTRACT:
This invention provides a method for determining susceptibility for an anti-viral drug comprising: (a) introducing a resistance test vector comprising a patient-derived segment and an indicator gene into a host cell; (b) culturing the host cell from (a); (c) measuring expression of the indicator gene in a target host cell; and (d) comparing the expression of the indicator gene from (c) with the expression of the indicator gene measured when steps (a)-(c) are carried out in the absence of the anti-viral drug, wherein a test concentration of the anti-viral drug is present at steps (a)-(c); at steps (b)-(c); or at step (c). This invention also provides a method for determining anti-viral drug resistance in a patient comprising: (a) determining anti-viral drug susceptibility in the patient at a first time using the susceptibility test described above, wherein the patient-derived segment is obtained from the patient at about said time; (b) determining anti-viral drug susceptibility of the same patient at a later time; and (c) comparing the anti-viral drug susceptibilities determined in step (a) and (b), wherein a decrease in anti-viral drug susceptibility at the later time compared to the first time indicates development or progression of anti-viral drug resistance in the patient. This invention also provides a method for evaluating the biological effectiveness of a candidate anti-viral drug compound. Compositions including resistance test vectors comprising a patient-derived segment and an indicator gene and host cells transformed with the resistance test vectors are provided.

REFERENCES:
patent: 4952496 (1990-08-01), Studier et al.
patent: 5126251 (1992-06-01), Moss et al.
patent: 5135855 (1992-08-01), Moss et al.
patent: 5354674 (1994-10-01), Hodgson
patent: 5462873 (1995-10-01), Garfinkel et al.
patent: 5874565 (1999-02-01), Rice et al.
patent: 6033902 (2000-03-01), Haseltine et al.
patent: 6127116 (2000-10-01), Rice et al.
patent: 6242187 (2001-06-01), Capon et al.
patent: 2002/0034732 (2002-03-01), Capon et al.
patent: 0 291 893 (1988-11-01), None
patent: WO91/19798 (1991-12-01), None
patent: WO92/07943 (1992-05-01), None
patent: WO94/08002 (1994-04-01), None
patent: WO94/19478 (1994-09-01), None
patent: WO94/29438 (1994-12-01), None
patent: WO95/22622 (1995-08-01), None
patent: WO97/27319 (1997-07-01), None
patent: WO97/27480 (1997-07-01), None
patent: WO99/06597 (1999-02-01), None
Blight et al., 2000, “Efficient Initiation of HCV RNA Replication in Cell Culture,”Science290:1972-1974.
Brown et al. 1994, “In Vitro Characterization of an Internal Ribosomal Entry Site (IRES) Present Within the 5' Nontranslated Region of Hepatitis A Virus RNA: Comparison with the IRES of Encephalomyocarditis Virus,”Journal of Virology68(2):1066-74.
Chou et al., 1995, “Frequency of UL97 Phosphotransferase Mutations Related to Ganciclovir Resistance in Clinical Cytomegalovirus Isolates,”The Journal of Infectious Diseases172:239-242.
Chung et al., 2001, “Hepatitis C Virus Replication is Directly Inhibited by IFN-α in a Full Length Binary Expression System,”Proc. Natl. Acad Sci USA, 98(17):9847-9852.
International Search Report PCT/US2003/013791 filed Apr. 2004.
Enami, et al., 1991, “High-Efficiency Formation of Influenza Virus Transfectants”Journal of Virology65(5):2711-13.
Fuerst et al., 1986, “Eukaryotic Transient-Expression System Based on Recombinant Vaccinia Virus That Synthesizes Bacteriophage T7 RNA Polymerase”Proc. Natl. Acad Sci USA, 83:8122-26.
Gerna et al., 1995, “Rapid Screening For Resistance to Ganciclovir and Foscarnet of Primary Isolates of Human Cytomegalovirus From Culture-Positive Blood Samples”Journal of Microbiology, 33(3):738-741.
Glass et al., 1993, “Identification of the Hepatitis A Virus Internal Ribosome Entry Site:In Vivo and In Vitro Analysis of Bicistronic RNAs Containing the HAV 5' Noncoding Region” Virology, 193:842-852.
Hahm et al., 1996, “Generation of a Novel Poliovirus with a Requirement of Hepatitis C Virus Protease NS3 Activity”Virology(1996) 226:318-326.
Hirowatari et al., 1995, “A Novel Method for Analysis of Viral Proteinase Activity Encoded by Hepatitis C Virus in Cultured Cells,”Analytical Biochemistry, 225:113-120.
Houghton et al., 1996, “Hepatitis C Viruses” Fields Virology 3rdEdition Chapter 32: 1035-1058.
Jang et al., 1989, “Initiation of Protein Synthesis by Internal Entry of Ribosomes into the 5' Nontranslated Region of Encephalomyocarditis Virus RNA In Vivo,”Journal of Virology, 63(4):1651-1660.
Lawson et al., 1995, “Recombinant Vesicular Stornatitis Viruses From DNA,”Proc Natl. Acad. Sci. USA, 63:4477-4481.
Lu et al., 1996, “Poliovirus Chimeras Replicating Under the Translational Control of Genetic Elements of Hepatitis C Virus Reveal Unusual Properties of the Internal Ribosomal Entry Site of Hepatitis C Virus,”Proc Natl. Acad. Sci. USA, 93: 1412-1417.
Mocarski, Edward S., 1996, “Cytomegaloviruses and Their Replication,”Fields Virology 3rdEdition Chapter76, 2447-22492.
Pelletier et al., 1988, “Internal Initiation of Translation of Eukaryotic mRNA Directed by a Sequence Derived From Poliovirus RNA,”Nature, 334:320-325.
Rohll et al., 1994, “The 5'-Untranslated Regions of Picornavirus RNAs Contain Independent Functional Domains Essential for RNA Replication and Translation,”Journal of Virology, 68(7): 4384-91.
Schnell et al., 1994, “Infectious Rabies Viruses From Cloned cDNA,”The EMBO Journal, 13(18):4195-4203.
Steinkuhler et al., 1996, “Activity of Purified Hepatitis C Virus Protease NS3 on Peptide Substrates,”Journal of Virology, 70(10):6694-6700.
Tsukiyama-Kohara et al., 1992, “Internal Ribosome Entry Site Within Hepatitis C Virus RNA,”Journal of Virology, 66(3):1476-1483.
Wang et al., 1993, “Translation of Huamn Hepatitis C Virus RNA in Cultured Cells is Mediated by an Internal Ribosome-Binding Mechanism,”Journal of Virology, 67(6):3338-3344.
European Search Report for EP Application 98940779.6 filed Aug. 9, 2004.
Enomoto et al. (1995) “Hepatitis C Virus Quasispecies Populations During Chronic Hepatitis C Infection”,Trends in Microbiology3(11):445-447.
Stair et al. (1993) “Recombinant Retroviral Systems for the Analysis of Drug Resistant HIV”,Nucleic Acids Research21(20):4836-4842.
International Search Report PCT/US97/01609 filed Oct. 1998.
International Search Report PCT/US98/15967 filed Oct. 1998.
Alam et al., “Reporter Genes: Application to the Study of Mammalian Gene Transcription,” (1990), Analytical Biochemistry 188:245-254.
Bernard, “Positive Selection of Recombinant DNA by CcdB,” (1996), Biotechniques 21:320-323.
Blight et al., “Efficient Initiation of HCV RNA Replication in Cell Culture,” (2000), Science 290:1972-1974.
Chalfie, “Green Fluorescent Protein,” (1995), Photochemistry and Photobiology, 67:651-656.
Cheng et al., “Specific Interaction Between the Hepatitis C Virus Ns5B RNA Polymerase and the 3' End of the Viral RNA,” (1999), J. Virol. 73:7044-7049.
Chowrira et al., “In VitroandIn VivoComparison of Hammerhead Hairpin, and Hepatitis Delta Virus Self Processing Ribozyme Cassettes,” (1994), J. Biol. Chem. 269:25856-25864.
Chung et al., “Hepatitis C Virus Replication is Directly Inhibited By IFN-α in a Full Length Binary Expression System,” (2001), 98:9847-9852.
Frese et al., “Interferon-γInhibits Replication of Subgenomic and Genomic Hepatitis C Virus RNAs,” (2002), Hepatology 35:694-703.
Gould et al., “Firefly Luciferase as a Tool in Molecular and Cell Biology,” (1988), Analytical Biochemistry 175:5-13.
Grakoui et al., “Characterization of the Hepatitis C Virus-Encoded Serine Proteinase: Determination of Proteinase-Dependent Polyprotein Cleavage Sites,” (1993),

Affiliated with

Also associated with

Rating

Compositions and methods for determining anti-viral drug... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compositions and methods for determining anti-viral drug..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for determining anti-viral drug... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3431273